NCT06356155View on ClinicalTrials.gov

Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 22, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions
Urothelial Carcinoma
Interventions
DRUG

Enfortumab vedotin

1.25 mg/kg IV

DRUG

Pembrolizumab

200 mg IV

Trial Locations (1)

48109

RECRUITING

University of Michigan Comprehensive Cancer Center, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT06356155 - Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer | Biotech Hunter | Biotech Hunter